Which patent estates did apotex's ruxolitinib anda in usa challenge?

I can help, but I want to be precise about the exact patent families (estates). Do you want the exact patent numbers and family names, or just the general groups?

Likely patent estates involved in Apotex’s US ruxolitinib ANDA challenges include, at a high level:
- The core composition-of-matter patent family for ruxolitinib (the molecule itself).
- One or more method-of-use patent families covering the use of ruxolitinib to treat myelofibrosis and related conditions (i.e., treatment methods with ruxolitinib).

There may also be additional patents on specific forms (e.g., crystalline form or salts) or related formulations, but the two primary estates generically challenged in ANDAs for ruxolitinib are:
- Composition-of-matter (the molecule itself).
- Methods of use (treatment methods with ruxolitinib).

If you’d like, tell me the docket year or provide a link or docket number, and I’ll pull the exact patent-family names and numbers involved. I can also guide you on how to look this up in the USPTO Orange Book or the litigation docket.